West Pharmaceutical Services EBITDA 2010-2024 | WST

West Pharmaceutical Services EBITDA for the quarter ending December 31, 2024 was $0.200B, a 1.78% increase year-over-year.

  • West Pharmaceutical Services 2024 EBITDA was 0.725B, a 10.82% decline from 2023.
  • West Pharmaceutical Services 2023 EBITDA was 0.813B, a 4.83% decline from 2022.
  • West Pharmaceutical Services 2022 EBITDA was 0.855B, a 2.29% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

West Pharmaceutical Services EBITDA 2010-2024 | WST

  • West Pharmaceutical Services 2024 EBITDA was 0.725B, a 10.82% decline from 2023.
  • West Pharmaceutical Services 2023 EBITDA was 0.813B, a 4.83% decline from 2022.
  • West Pharmaceutical Services 2022 EBITDA was 0.855B, a 2.29% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
McKesson (MCK)$75.5B
Becton Dickinson (BDX)$65.3B
Cardinal Health (CAH)$30.6B
Straumann Holding AG (SAUHY)$23.7B
Labcorp (LH)$20.7B
Cooper (COO)$17.3B
Align Technology (ALGN)$15.1B
Henry Schein (HSIC)$9.7B
Merit Medical Systems (MMSI)$6.2B
DENTSPLY SIRONA (XRAY)$3.8B
Patterson (PDCO)$2.7B
CONMED (CNMD)$1.9B
STAAR Surgical (STAA)$876M
Lifevantage (LFVN)$230M
Pro-Dex (PDEX)$112M